Renin–angiotensin system inhibition and mortality in patients undergoing dialysis with coronary artery disease: insights from a multi-center observational study
Expert Review of Clinical Pharmacology · 2024
DOI: 10.1080/17512433.2024.2419915 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Expert Review of Clinical Pharmacology, 2024. Verfasst von Enmin Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, China-Japan Friendship Hospital, Beijing, China. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Coronary Artery Disease, Renal Dialysis, Angiotensin Receptor Antagonists. Die Arbeit nennt 46 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, the Science Foundation of China-Japan Friendship Hospital, National Key Clinical Specialty Construction Project.
Abstract (Originalsprache)
BACKGROUND: While the survival benefits of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are firmly established in the general population, their efficacy within patient undergoing dialysis with coronary artery disease (CAD) remains controversial. METHODS: Between January 2015 and June 2021, 1168 patients undergoing dialysis with CAD were assessed from 30 tertiary medical centers. The primary outcome was all-cause death, and the secondary outcome was cardiovascular death. Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were performed to account for between-group differences. RESULTS: Overall, ACEI or ARB were prescribed to 518 patients (44.3%) upon discharge. After a median follow-up of 22.2 months, 361 (30.9%) patients died, including 243 cardiovascular deaths. The use of ACEI or ARB was associated with a significantly lower risk of all-cause (25.3% vs 35.4%, hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.52-0.82, p < 0.001) and cardiovascular death (17.0% vs 23.8%; HR 0.64, 95% CI 0.48-0.83, p = 0.001). These findings remained consistent across IPTW and PSM analyses. Sensitivity analyses for ACEI and ARB use separately yielded similar results. CONCLUSIONS: Our findings suggested that among patients undergoing dialysis with CAD, ACEI or ARB use was associated with a lower risk of all-cause and cardiovascular death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.
- Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
- Department of Cardiology, Fuwai Central China Cardiovascular Hospital, Zheng zhou, Henan, China.
- Department of Cardiology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.
Förderung
- National High Level Hospital Clinical Research Funding
- the Science Foundation of China-Japan Friendship Hospital
- National Key Clinical Specialty Construction Project
Zitieren
APA
Xie, E., An, S., Wu, Y., Ye, Z., Zhao, X., Li, Y., Shen, N., Gao, Y., & Zheng, J. (2024). Renin–angiotensin system inhibition and mortality in patients undergoing dialysis with coronary artery disease: insights from a multi-center observational study. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2024.2419915
Vancouver
Xie E, An S, Wu Y, Ye Z, Zhao X, Li Y, et al. Renin–angiotensin system inhibition and mortality in patients undergoing dialysis with coronary artery disease: insights from a multi-center observational study. Expert Review of Clinical Pharmacology. 2024. doi:10.1080/17512433.2024.2419915
BibTeX
@article{Xie2024,
author = {Xie, Enmin and An, Shuoyan and Wu, Yaxin and Ye, Zixiang and Zhao, Xuecheng and Li, Yike and Shen, Nan and Gao, Yanxiang and Zheng, Jingang},
title = {Renin–angiotensin system inhibition and mortality in patients undergoing dialysis with coronary artery disease: insights from a multi-center observational study},
journal = {Expert Review of Clinical Pharmacology},
year = {2024},
doi = {10.1080/17512433.2024.2419915}
}
EUVIMED